Elevance Health Reaffirms Full Year 2026 Financial & Benefit Ratio Guidance

Executive Summary

On September 10, 2026, Elevance Health, Inc. (NYSE: ELV) furnished a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) to reaffirm its full-year 2026 financial guidance ahead of scheduled investor and analyst meetings.

---

Guidance Details

• GAAP Shareholders' Earnings per Diluted Share: Expected to be at least $20.10, inclusive of approximately $6.90 per diluted share of net unfavorable items.
• Adjusted Shareholders' Earnings per Diluted Share: Expected to be at least $27.00, excluding the aforementioned net unfavorable items. The guidance incorporates no other adjustment items beyond those reported in the Q2 2026 earnings.
• Benefit Expense Ratio (Medical Loss Ratio): Reaffirmed at 90.2% ± 50 basis points for full-year 2026.

---

Market & Strategic Context

• Investor Relations Activity: Company officers will be engaging in meetings with analysts and institutional investors over the next several weeks.
• Stability in Core Metrics: Reaffirming the benefit expense ratio within a 90.2% range signals continued visibility into medical cost trends and healthcare utilization rates heading into the second half of 2026.
• Regulatory Status: Furnished under Item 7.01 and not deemed "filed" for purposes of Section 18 of the Exchange Act.